Clinical Trial

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-02.
Status change: Not Yet Recruiting → Recruiting 2025-06-24
Trial Details
NCT Number NCT07003074
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Breast Cancer
Enrollment 642 participants
Start Date 2025-06-23
Primary Completion 2029-07 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2025-06-25